Hansa Biopharma to Host Conference Call to Provide First Quarter 2019 Business Update
On 29 April 2019, at 08:00AM CET, Hansa Biopharma will publish its Business Update for the first quarter of 2019. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 2:00PM CET. The event will be hosted by Hansa Biopharma’s CEO and President, Søren Tulstrup, and the presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under Events & Webcast, and will also be made available online after the call. To participate in the telephone conference, please use the dial in details shown below:
SE: +46 850-558 355
UK: +44 3333 009 035
US: +1 833 526 83 47
A link to audio cast can be found on the Hansa Biopharma website under Events & Webcasts or here:
The information was submitted for publication, through the agency of the contact person set out below at 11:00am CET on April 23, 2019.
About Hansa Biopharma
Hansa Biopharma AB (NASDAQ Stockholm: HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product, IDEFIRIX (imlifidase), is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa’s research and development program is advancing the next generation of the Company’s technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.
For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ)
Mobile: +46 (0) 707-17 54 77
Swedish Investor and Media Relations:
Cord Communications Mikael Widell
+46 70-311 99 60
U.K. Investor and Media Relations:
Simon Conway / Natalie Garland-Collins
+44 (0)20 3727 1000
U.S. Investor and Media Relations:
Stephanie Marks / David Rosen (media)
+1 212 600 1902